Humana Inc. (NYSE:HUM) Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB decreased its position in Humana Inc. (NYSE:HUM) by 1.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 41,707 shares of the insurance provider’s stock after selling 481 shares during the quarter. Handelsbanken Fonder AB’s holdings in Humana were worth $19,094,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in HUM. Ameriprise Financial Inc. grew its position in shares of Humana by 35.9% in the 3rd quarter. Ameriprise Financial Inc. now owns 1,523,835 shares of the insurance provider’s stock worth $741,409,000 after acquiring an additional 402,559 shares in the last quarter. AQR Capital Management LLC grew its position in shares of Humana by 39.3% in the 3rd quarter. AQR Capital Management LLC now owns 681,868 shares of the insurance provider’s stock worth $331,743,000 after acquiring an additional 192,546 shares in the last quarter. Quadrature Capital Ltd grew its position in shares of Humana by 814.5% in the 3rd quarter. Quadrature Capital Ltd now owns 181,787 shares of the insurance provider’s stock worth $88,448,000 after acquiring an additional 161,909 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its position in shares of Humana by 2,659.2% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 152,860 shares of the insurance provider’s stock worth $74,369,000 after acquiring an additional 147,320 shares in the last quarter. Finally, International Assets Investment Management LLC lifted its holdings in shares of Humana by 32,648.4% in the 4th quarter. International Assets Investment Management LLC now owns 134,596 shares of the insurance provider’s stock worth $61,619,000 after purchasing an additional 134,185 shares during the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Stock Down 0.9 %

Shares of HUM stock opened at $325.30 on Tuesday. Humana Inc. has a 1 year low of $299.23 and a 1 year high of $541.21. The stock has a market cap of $39.25 billion, a PE ratio of 16.41, a price-to-earnings-growth ratio of 1.92 and a beta of 0.45. The business’s fifty day moving average is $330.09 and its 200-day moving average is $399.70. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.59 and a current ratio of 1.59.

Humana (NYSE:HUM) last issued its quarterly earnings results on Thursday, January 25th. The insurance provider reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.87). Humana had a net margin of 2.34% and a return on equity of 19.44%. The firm had revenue of $26.46 billion for the quarter, compared to analyst estimates of $25.47 billion. During the same quarter last year, the business posted $1.62 earnings per share. The firm’s revenue for the quarter was up 17.9% compared to the same quarter last year. Equities analysts expect that Humana Inc. will post 16.06 earnings per share for the current fiscal year.

Humana Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 1.09%. The ex-dividend date of this dividend is Friday, June 28th. Humana’s dividend payout ratio (DPR) is presently 17.86%.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Stephens cut their price target on Humana from $550.00 to $430.00 and set an “overweight” rating on the stock in a report on Friday, January 26th. Cantor Fitzgerald reissued a “neutral” rating and issued a $391.00 price target on shares of Humana in a report on Wednesday, April 10th. Raymond James assumed coverage on Humana in a report on Friday, March 22nd. They issued a “market perform” rating on the stock. TheStreet downgraded Humana from a “b” rating to a “c+” rating in a report on Monday, January 8th. Finally, Deutsche Bank Aktiengesellschaft downgraded Humana from a “buy” rating to a “hold” rating and cut their price target for the stock from $595.00 to $360.00 in a report on Thursday, January 25th. Eleven research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $454.63.

Insider Activity

In other news, Director Jorge S. Mesquita purchased 545 shares of the stock in a transaction dated Tuesday, February 20th. The shares were bought at an average cost of $367.09 per share, for a total transaction of $200,064.05. Following the transaction, the director now owns 2,578 shares in the company, valued at $946,358.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.29% of the stock is owned by insiders.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.